Clinical trials: Esophageal Diseases
Gastroesophageal Reflux
ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)
Evaluation of the effect of ADX10059 on symptom control in patients with gastroesophageal reflux.
- Trial name
- NCT00820079
- Testing
- ADX10059
- Where
- 11 sites in Austria, Belgium and 2 more
- Volunteers
- 120 people
- Sponsor
- Addex Pharma S.A.
NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC
- Trial name
- NCT07085091
- Testing
- ALX2004
- Where
- 12 sites in United States
- Volunteers
- 170 people
- Sponsor
- ALX Oncology Inc.
Gastroesophageal Reflux Disease (GERD)
Medigus Ultrasonic Surgical Endostapler (MUSE) Registry
This registry is intended as an observational, post-marketing surveillance tool. The registry allows collection of baseline demographics and user experience of the commercially available MUSE system.
- Trial name
- NCT02366169
- Testing
- Medigus Ultrasonic Surgical Endostapler (MUSE) Procedure
- Where
- 16 sites in United States, Germany and 1 more
- Volunteers
- 200 people
- Sponsor
- Medigus Ltd
Barrett's Esophagus, High Grade Dysplasia
Study of CryoSpray Ablation of Low Grade or High Grade Dysplasia Within Barrett's Esophagus
The purpose of this study is to evaluate the safety and effectiveness of the CryoSpray Ablation System to treat esophageal low grade dysplasia (LGD) or high grade dysplasia (HGD) within Barrett's Esophagus (BE).
- Conditions
- Barrett's Esophagus, High Grade Dysplasia, Low Grade Dysplasia
- Trial name
- ICE (NCT00526786)
- Testing
- CryoSpray Ablation System (510(k) NO: K070893)
- Where
- 16 sites in United States
- Volunteers
- 78 people
- Sponsor
- CSA Medical, Inc.
Gastrointestinal Tumors, Colorectal Adenocarcinomas
Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.
A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors
- Conditions
- Gastrointestinal Tumors, Colorectal Adenocarcinomas, Gastric Adenocarcinomas, Esophageal Adenocarcinomas
- Trial name
- NCT04171141
- Testing
- PF-07062119, Anti-PD1, Anti-VEGF
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Pfizer
Symptomatic Non-erosive Gastroesophageal Reflux Disease
A Study to Evaluate the Efficacy and Safety of Vonoprazan 10 mg Compared to Placebo for Relief of Episodic Heartburn in Participants With Symptomatic Non-Erosive Gastroesophageal Reflux Disease Through 24 Weeks
The main objective is to assess the efficacy of vonoprazan (10 mg as needed) compared to placebo (as needed) in relief of episodic heartburn at 2 hours that is sustained for 24 hours over 12 weeks of treatment in participants…
- Trial name
- NCT07752407
- Testing
- Vonoprazan
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Phathom Pharmaceuticals, Inc.
Biliary Tract Cancer, Breast Cancer
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.
- Conditions
- Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer
- Trial name
- NCT06239194
- Testing
- MDX2001
- Where
- 6 sites in United States
- Volunteers
- 330 people
- Sponsor
- ModeX Therapeutics, An OPKO Health Company
Esophageal Squamous Cell Carcinoma
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
This is a randomized, double-blind, multicenter, Phase 3 study to compare the efficacy and safety of LY01015 and Opdivo®（Nivolumab Injection）combined respectively with fluorouracil plus cisplatin in participants with unresectable…
- Trial name
- NCT06022861
- Testing
- LY01015, Fluorouracil, Cisplatin
- Where
- China
- Volunteers
- 510 people
- Sponsor
- Shandong Boan Biotechnology Co., Ltd
Gastroesophageal Reflux Disease
A Post-market Registry to Assess Safety and Performance of RefluxStop™ in the Treatment of GERD in General Hospital Practice
A post-market retrospective and prospective, open label, multicenter, single-arm registry study using standard clinical procedures to record available and/or new data to evaluate the safety and performance of RefluxStop™ for the…
- Trial name
- RESTORE500 (NCT07004439)
- Testing
- RefluxStop™ implantation
- Where
- 5 sites in Germany, Spain
- Volunteers
- 500 people
- Sponsor
- Implantica CE Reflux Ltd.
Candidiasis, Esophageal, HIV Infections
Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients
To determine the appropriate duration of amphotericin B therapy for Candida esophagitis. To compare the effectiveness of two different amphotericin B doses in the treatment of biopsy-proven Candida esophagitis.
- Trial name
- NCT00002041
- Testing
- Amphotericin B
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
Esophageal Cancer, Adenocarcinoma of the Esophagus
Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
OncoGel is a new experimental drug delivery system that allows the slow continuous release of paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel) over a long period of time.
- Conditions
- Esophageal Cancer, Adenocarcinoma of the Esophagus, Squamous Cell Carcinoma
- Trial name
- NCT00573131
- Testing
- OncoGel (Paclitaxel gel), cisplatin, 5-FU
- Where
- 20 sites in United States, Czechia and 2 more
- Volunteers
- 137 people
- Sponsor
- Boston Scientific Corporation
Neoplasms, Gastrointestinal Tract
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
The study will determine if changes in expression of markers involved in the 5-FU pathways are associated with response to treatment with the combination of lapatinib and capecitabine independent of tumor erbB2 status.
- Trial name
- NCT00526669
- Testing
- Lapatinib and Capecitabine
- Where
- 22 sites in United States, Canada and 4 more
- Volunteers
- 68 people
- Sponsor
- GlaxoSmithKline
Gastroesophageal Reflux Disease
A Study to Evaluate the Improvement Effect on Subjective Symptom of FEXUCLUE Tab
This observation study is a large-scale, prospective, and multi-organ observation study to observe the improvement effect of the self-evaluation results (PRO) of erosive gastroesophageal reflux disease at least 4 to 8 weeks after…
- Trial name
- NCT05660122
- Testing
- Fexuprazan Hydrochloride
- Where
- South Korea
- Volunteers
- 2,852 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Gastroesophageal Reflux Disease
Effect of Long-Term Electrical Stimulation on LES Pressure and Esophageal Acid Exposure in Patients With GERD
The EndoStim LES Stimulation System is an investigational device intended to improve the LES pressure and restore Lower Esophageal Sphincter (LES) function in individuals suffering from Gastroesophageal Reflux Disease (GERD).
- Trial name
- NCT01574339
- Testing
- EndoStim LES Stimulation System
- Where
- 10 sites in Chile, Colombia and 6 more
- Volunteers
- 42 people
- Sponsor
- EndoStim Inc.
Gastroesophageal Reflux
Prevalence of Gastroesophageal Reflux During Childhood and Teenage Years in France
The purpose of this study is to assess prevalence of gastrooesophageal reflux during childhood and teenage years in France and to describe patients'symptoms and gastrooesophageal reflux management
- Trial name
- NCT00681837
- Where
- 25 sites in China
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Gastric-Esophageal Cancer
Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer
The goal of this clinical trial is to assess if circulating tumor DNA, as assessed by Signatera tumor-informed MRD assay, can guide de-escalation of adjuvant therapy in patients with resectable Stage II-IVa…
- Trial name
- SIGNAL GEC-101 (NCT07565857)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 1,000 people
- Sponsor
- Natera, Inc.
Swallowing Disorders
NewBreez Safety and Efficacy Evaluation
The objective of this clinical study is to evaluate the safety and efficacy of the NewBreez intra-laryngeal implant in patients with dysfunctional larynx.
- Trial name
- NCT01587664
- Testing
- NewBreez ILP
- Where
- 2 sites in Belgium, France
- Volunteers
- 2 people
- Sponsor
- ProTiP Medical
Esophageal Squamous Cell Carcinoma, Gastric Carcinoma, Gastroesophageal Junction Carcinoma
BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma
This is a Phase 2, multi-cohort study to investigate safety, PK, and preliminary anti-tumor activity of the monoclonal antibody BGB A317 in combination with standard chemotherapy as first-line treatment.
- Trial name
- NCT03469557
- Testing
- Tislelizumab, Cisplatin, 5-FU
- Where
- 6 sites in China
- Volunteers
- 30 people
- Sponsor
- BeiGene
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in…
- Conditions
- Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC
- Trial name
- NCT03114319
- Testing
- TNO155, TNO155 in combination with EGF816 (nazartinib)
- Where
- 18 sites in United States, Canada and 7 more
- Volunteers
- 227 people
- Sponsor
- Novartis Pharmaceuticals
Gastric Cancer
First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma
This is a phase 3, multicenter, randomized, double-blind, placebo controlled study of epirubicin, cisplatin \& capecitabine (ECX) with rilotumumab or placebo for untreated advanced MET-positive gastric or gastroesophageal…
- Trial name
- RILOMET-1 (NCT01697072)
- Testing
- Rilotumumab, Epirubicin, Cisplatin
- Where
- 189 sites in United States, Australia and 25 more
- Volunteers
- 609 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.